- (PLX AI) - Genmab's recent share slump is a buying opportunity, analysts at Nordea said, maintaining an unchanged price target of DKK 3,191.
- • Investors should add to positions ahead of the J&J Pharma Business Review day on Nov. 18, Nordea said
- • Genmab has historically performed well after such events: Nordea
- • Price target implies 17% upside
© 2021 PLX AI
